Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CGD-RIST2 reduced-intensity allogeneic stem cell transplantation for chronic granulomatous disease
jRCTs031180398Phase 2Recruiting
- Sponsor
- National Center for Child Health and Development
- Start
- May 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of busulfan, fludarabine and antithymocyte globulin rabbit in chronic granulomatous disease (CGD), sponsored by National Center for Child Health and Development. Started May 2018; status: recruiting.
02
Drugs
busulfanfludarabineantithymocyte globulin rabbit
03
Conditions
chronic granulomatous disease (CGD)
Beyond the preview
Go deeper on jRCTs031180398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180398.